Vancouver, British Columbia – Abdera Therapeutics Inc., a precision oncology company developing next-generation targeted radiation therapies, has announced the successful completion of its Series B funding round, raising $142 million. The round was led by Viking Global Investors and Qiming Venture Partners USA, with participation from RTW Investments, LP, Amplitude Ventures, Versant Ventures, venBio, Northview LifeSciences, adMare BioInnovations, and AbCellera.

Founded by Lori Lyons-Williams, Abdera Therapeutics is based in Vancouver, British Columbia, Canada, and is focused on developing cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells.

This new funding will support the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options. The precision oncology company will also expand its technology platform and advance its research and development efforts.

"We are thrilled to have the support of such esteemed investors, who share our vision for advancing precision oncology and developing next-generation targeted radiation therapies," said Lori Lyons-Williams, Founder and CEO of Abdera Therapeutics. "This funding will enable us to further our research and development efforts and bring our innovative therapies to patients who desperately need them."

For more information on Abdera Therapeutics, please visit https://abderatx.com/